PMID- 27562320 OWN - NLM STAT- MEDLINE DCOM- 20170531 LR - 20220409 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 193 DP - 2016 Dec 4 TI - Bufei Yishen granules combined with acupoint sticking therapy suppress oxidative stress in chronic obstructive pulmonary disease rats: Via regulating peroxisome proliferator-activated receptor-gamma signaling. PG - 354-361 LID - S0378-8741(16)30553-0 [pii] LID - 10.1016/j.jep.2016.08.027 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Traditional Chinese medicine (TCM) is clinically used under the guidance of its unique theory system. Bufei Yishen (BY) granules, an oral Chinese herbal formula, is confirmed effective for treating the syndrome of lung-kidney qi deficiency in chronic obstructive pulmonary disease (COPD) patients. Shu-Fei Tie ointment is another prescription for acupoint sticking (AS) therapy based on the theory of treating an internal disease by external treatment on proper acupoints. The beneficial effects of BY granules combined with Shu-Fei Tie have been proved in previous clinical trials. However, the underlying mechanism remains unclear. The present study was initiated to explore the antioxidative mechanism of the integrated therapy of BY granules and acupoint sticking via regulating by peroxisome proliferator activated receptor-gamma (PPARgamma) signaling in a cigarette-smoke/bacterial exposure induced COPD rat model. MATERIALS AND METHODS: Rats were randomized into Control, Model, BY, AS, BY+AS and aminophylline (APL) groups. COPD rats were induced by cigarette-smoke and bacterial exposures, and were administrated with normal saline, BY granules, AS, BY+AS or aminophylline from week 9 and sacrificed at week 20. Activity of superoxide dismutase (SOD) and levels of methane dicarboxylic aldehyde (MDA) in peripheral blood and bronchoalveolar lavage fluid (BALF) were determined by hydroxylamine and thiobarbituric acid methods. The gene and protein expressions of PPARgamma in the lung tissues were analyzed by quantitative polymerase chain reaction and western blot. RESULTS: Serum and BALF SOD decreased significantly in Model group (P<0.01), while MDA increased (P<0.01). Compared to COPD rats, serum SOD was higher in all treatment groups (P<0.01), and BALF SOD was higher in BY and BY+AS groups (P<0.01); serum and BALF MDA was lower in all treatment groups (P<0.01). Serum and BALF SOD was higher in BY+AS group than in AS group, while MDA was lower (P<0.05). BALF SOD increased in BY+AS group compared with APL group, while MDA decreased (P<0.05). PPARgamma mRNA and protein and the phosphorylation of PPARgamma (p-PPARgamma) decreased in COPD rats (P<0.01), and increased in all treatment groups (P<0.01). PPARgamma mRNA was higher in BY+AS group than in AS group (P<0.05), PPARgamma and p-PPARgamma were higher in BY+AS group than in AS and APL groups (P<0.05, P<0.01); PPARgamma protein was higher in BY group than in APL group (P<0.05). CONCLUSION: Bufei Yishen granules, Shu-Fei Tie and their combination have beneficial effects in stable COPD, and can attenuate the oxidative stress, and the activation of PPARgamma signaling might be involved in the underlying mechanisms, but there are no obvious synergistic effect of Bufei Yishen granules and Shu-Fei Tie. CI - Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved. FAU - Li, Ya AU - Li Y AD - Institute for Respiratory Diseases, the First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou, Henan 450000, China; Central Laboratory, the First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou, Henan 450000, China; The Collaborative Innovation Center for Respiratory Diseases Diagnostics, Treatment and New Drug Research and Development in Henan Province, Zhengzhou, Henan 450046, China. Electronic address: yuanfengtcm@126.com. FAU - Tian, Yan-Ge AU - Tian YG AD - The Collaborative Innovation Center for Respiratory Diseases Diagnostics, Treatment and New Drug Research and Development in Henan Province, Zhengzhou, Henan 450046, China; Institute for Geriatrics, Henan University of Chinese Medicine, Zhengzhou, Henan 450046, China. Electronic address: yange0910@126.com. FAU - Li, Jian-Sheng AU - Li JS AD - Institute for Respiratory Diseases, the First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou, Henan 450000, China; The Collaborative Innovation Center for Respiratory Diseases Diagnostics, Treatment and New Drug Research and Development in Henan Province, Zhengzhou, Henan 450046, China; Institute for Geriatrics, Henan University of Chinese Medicine, Zhengzhou, Henan 450046, China. Electronic address: li_js8@163.com. FAU - Dong, Yu-Qiong AU - Dong YQ AD - Institute for Respiratory Diseases, the First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou, Henan 450000, China. Electronic address: dyq865239@163.com. FAU - Wang, Ming-Hang AU - Wang MH AD - Institute for Respiratory Diseases, the First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou, Henan 450000, China; The Collaborative Innovation Center for Respiratory Diseases Diagnostics, Treatment and New Drug Research and Development in Henan Province, Zhengzhou, Henan 450046, China. Electronic address: wmh107hn@163.com. FAU - Feng, Su-Xiang AU - Feng SX AD - The Collaborative Innovation Center for Respiratory Diseases Diagnostics, Treatment and New Drug Research and Development in Henan Province, Zhengzhou, Henan 450046, China. Electronic address: fengsx221@163.com. FAU - Li, Lin-Lin AU - Li LL AD - Institute for Geriatrics, Henan University of Chinese Medicine, Zhengzhou, Henan 450046, China. Electronic address: liheli90@163.com. FAU - Mao, Jing AU - Mao J AD - Institute for Respiratory Diseases, the First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou, Henan 450000, China. Electronic address: 13838149747@163.com. FAU - Wang, Li-Li AU - Wang LL AD - Institute for Respiratory Diseases, the First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou, Henan 450000, China. Electronic address: lucy6835@163.com. FAU - Luo, Shan AU - Luo S AD - Institute for Respiratory Diseases, the First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou, Henan 450000, China. Electronic address: hnzyglyst@126.com. LA - eng PT - Journal Article DEP - 20160822 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Bu-Fei-Yi-Shen) RN - 0 (Drugs, Chinese Herbal) RN - 0 (PPAR gamma) RN - 0 (Placebos) RN - 0 (RNA, Messenger) RN - 4Y8F71G49Q (Malondialdehyde) RN - EC 1.15.1.1 (Superoxide Dismutase) SB - IM MH - *Acupuncture Points MH - Animals MH - Bronchoalveolar Lavage Fluid MH - *Disease Models, Animal MH - *Drugs, Chinese Herbal MH - Female MH - Lung/enzymology/metabolism MH - Male MH - Malondialdehyde/metabolism MH - *Oxidative Stress MH - PPAR gamma/genetics/*metabolism MH - Placebos MH - Pulmonary Disease, Chronic Obstructive/metabolism/*therapy MH - RNA, Messenger/genetics MH - Rats MH - Rats, Sprague-Dawley MH - *Signal Transduction MH - Superoxide Dismutase/blood/metabolism OTO - NOTNLM OT - 3,3'-diaminobenzidine (PubChem CID:7071) OT - Agarose (PubChem CID: 11966311). OT - Bufei Yishen granules OT - Ethanol (PubChem CID: 702) OT - Formaldehyde (PubChem CID: 712) OT - Hydroxylamine (PubChem CID: 787) OT - Oxidative stress OT - PPARgamma signaling OT - Phosphate-buffered saline (PubChem CID: 24978514) OT - Sodium dodecyl sulfate (PubChem CID: 3423265) OT - Thiobarbituric acid (PubChem CID: 2723628) OT - Xylene (PubChem CID: 7237) OT - acupoint sticking OT - chronic obstructive pulmonary disease EDAT- 2016/08/27 06:00 MHDA- 2017/06/01 06:00 CRDT- 2016/08/27 06:00 PHST- 2015/12/04 00:00 [received] PHST- 2016/08/11 00:00 [revised] PHST- 2016/08/20 00:00 [accepted] PHST- 2016/08/27 06:00 [pubmed] PHST- 2017/06/01 06:00 [medline] PHST- 2016/08/27 06:00 [entrez] AID - S0378-8741(16)30553-0 [pii] AID - 10.1016/j.jep.2016.08.027 [doi] PST - ppublish SO - J Ethnopharmacol. 2016 Dec 4;193:354-361. doi: 10.1016/j.jep.2016.08.027. Epub 2016 Aug 22.